SCHEMBL979978

SCHEMBL979978

COc1ccc(CC(=O)N2CCC(c3ccco3)=N2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
HSD17B10 Q99714 4/20 0.55
HPGD P15428 3/20 0.55
KMT2A Q03164 1/20 0.55
SMN1; SMN2 Q16637 5/20 0.53
RAB9A P51151 2/20 0.53
MAPT P10636 2/20 0.45
KDM4E B2RXH2 2/20 0.43
SIRT1 Q96EB6 1/20 0.43
F2 P00734 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HIF1A Q16665 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
ADORA2B P29275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980368 0.88 SIGMAR1 (0.47) ALDH1A1HSD17B10HPGDKMT2ASMN1; SMN2
SCHEMBL17004389 0.86 ALDH1A1 (0.50) ALDH1A1HSD17B10HPGDKMT2ASMN1; SMN2
SCHEMBL981923 0.85 POLB (0.41) ALDH1A1HPGDSMN1; SMN2RAB9AMAPT
SCHEMBL980150 0.82 ALDH1A1 (0.76) ALDH1A1HSD17B10HPGDSMN1; SMN2RAB9A
SCHEMBL980235 0.81 ALDH1A1 (0.60) ALDH1A1HSD17B10HPGDSMN1; SMN2RAB9A
SCHEMBL979286 0.79 ALDH1A1 (0.71) ALDH1A1HSD17B10HPGDKMT2ASMN1; SMN2
SCHEMBL980134 0.79 ALDH1A1 (0.54) ALDH1A1HSD17B10HPGDKMT2ASMN1; SMN2
SCHEMBL979315 0.78 ALDH1A1 (0.53) ALDH1A1HSD17B10HPGDKMT2ASMN1; SMN2
SCHEMBL982035 0.78 ALDH1A1 (0.53) ALDH1A1HSD17B10HPGDKMT2ASMN1; SMN2
SCHEMBL980195 0.77 SMN1; SMN2 (0.68) ALDH1A1HSD17B10HPGDKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 ALDH1A1 399/4885HSD17B10 691/4885HPGD 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.